Álvaro Sánchez is an experienced Mass Spectrometry specialist with over eight years of expertise in Proteomics, Immunopeptidomics and Small Molecules.
His educational background includes a BSc. in Biotechnology and an MSc. in HIV Immunopathology and Treatment from the University of Barcelona, that combined an internship at the University of Oxford, and resulted in the work published in the paper “Early Kinetics of the HLA Class-I associated peptidome of MVA.HIVconsv-Infected Cell” (J Virol 2015 Jun).
His academic activities led to the development of innovative methods for characterization of immunopeptides and monitorization of T-cell responses towards HIV-1, and contributed to research publications in Cancer and Infectious Diseases Immunotherapy (“The HLA Ligandome Comprises a Limited Repertoire of O-GlcNAcylated Antigens Preferentially Associated With HLA-B*07:02¨ Frontiers Immunol 2021 Dec).
Prior to joining EpiDisease Álvaro conducted pioneering research to identify immunopeptides as targets for immunotherapy of Cancer and developing applications to measure Small Molecules, utilizing advanced mass spectrometry techniques for leading companies such as Enara Bio (Oxford, UK) and Thermo Fisher Scientific.
¨I feel that EpiDisease is where my expertise can truly shine, and I can really make a difference. I am excited to be part of a team that shares my passion for improving patient lives by providing clinicians with precision tools to support them in their data-based decision making, and helping to drive scientific innovation. «
We are very excited at EpiDisease about the possibilities that Álvaro brings with his knowledge and expertise. We look towards a bright and successful future with him as a key part of our Team developing the next generation of precision clinical tools for diagnosis, prognosis and management of complex pathologies using the mass spectrometry technology platform.
Joining EpiDisease was a natural choice for me, and I cannot wait to contribute to the pioneering work that the Team is carrying out to transform healthcare and clinical discovery in the field of Precision Medicine and Biomarkers.¨
